O-003Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC)

Introduction: Nab-paclitaxel added to standard gemcitabine significantly improves overall survival, progression-free survival and response rates when compared to gemcitabine alone in metastatic PDAC. Baseline quality of life (QOL) indicators such as global health status (GHS) may be predictive for survival in this disease setting, together with clinical variables and tumour markers.

https://ift.tt/2K5Fz3D